Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral palsy can develop from several factors such as lack of oxygen to the brain, genetic conditions, brain infections, brain hemorrhage, chemical or substance abuse during pregnancy, injury to the head, and severe jaundice.
The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.
Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.
The Americas is expected to dominate the global cerebral palsy market during the forecast period owing to the well-established healthcare sector, growing awareness about CP, and the rising prevalence of cerebral palsy in the region. The European market is expected to be the second-largest market due to the growing healthcare expenditure and increasing prevalence of cerebral palsy. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to the developing healthcare infrastructure, and favorable government initiatives for the healthcare sector. The Middle East & Africa is likely to account for the least cerebral palsy market share over global market owing to the lack of economic development, especially in the African region.
Some of the prominent players in the global cerebral palsy market are Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd.
The global cerebral palsy market has been segmented into type, diagnosis, and treatment.
The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.
The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.
The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.
Browse More Report Details @ https://www.marketresearchfuture.com/reports/cerebral-palsy-market-6334